APLN and pulmonary arterial hypertension: Expression of its endogenous ligand apelin is reduced in the circulation of patients with Group 1 pulmonary hypertension, including idiopathic PAH, PAH associated with drugs or toxins, and autoimmune disease (Chandra et al., 2011; Goetze et al., 2006).